ClinicalTrials.gg
RecruitingNCT06779578Updated Jan 17, 2025

Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia

An interventional study of Bipolar pulsed radiofrequency and Mopolar pulsed radiofrequency in Trigeminal Neuralgia and Refractory Pain, sponsored by Alexandria University. Recruiting at 2 sites in Egypt. Per ClinicalTrials.gov, last updated 2025-01-17.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Jan 2024, registered Jan 2025).
  • Started Jan 2024; still recruiting 2 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Sex
All
01

Study summary

A prospective exploratory study aiming at comparing pulsed bipolar versus pulsed unipolar radiofrequency ablation in patients with medically refractory trigeminal neuralgia.

Read the detailed description

This will be a prospective exploratory that will be conducted on patients with the inclusion and exclusion criteria detailed.

At the baseline visit, the sociodemographic data (age, sex, smoking status) and clinical data (TN etiology (idiopathic or symptomatic), TN phenotype (purely paroxysmal or with concomitant continuous pain), clinical symptoms topography (V2, V3), brain MRI findings, previous medications and interventions, and comorbidities) will be collected. The patients will be randomly assigned to undergo bipolar PRF or monopolar PRF using a simple randomization technique.

Pain scores will be assessed using the nominal rating scale (NRS) at baseline, within two weeks postoperatively, and at 1-month, 3-month, and 6-month intervals. Patient satisfaction will be assessed within two weeks following the intervention on a five-point Likert scale (5 represents very good and 1 means very bad). Treatment success will be defined as at least a 50% reduction in pain scores. The duration to pain control and the duration to pain recurrence/rebound will be assessed at follow-up visits. The patient's postoperative need for medications or further pain interventions will be detailed. Intraoperative and postinterventional complications will be monitored and documented.

Study interventions For the PRF procedure, all patients will be prepared in the operating room and will undergo standard operative monitoring (i.e., blood pressure, electrocardiography, and pulse oximetry). They will be positioned in a supine position with slight neck extension. Sedation will be provided (100 Ig fentanyl and 2 mg midazolam intravenously). Skin preparation will be performed using chlorhexidine.

I- Monopolar PRF In the monopolar PRF, an RF cannula (22-gauge, 100 mm, with a 10 mm active tip (SMK)) will be percutaneously advanced at the posterior border of the foramen ovale under fluoroscopic guidance. For confirming the detection of the mandibular nerve, sensory stimulation will be performed via the radiofrequency generator at a current of 0.5 to 1 V at a frequency of 50 Hz to elicit paresthesia response in the mandibular region. Motor stimulation will be performed via the generator at a current of 1 - 2 V applied at a frequency of 2 Hz to obtain a contraction response at the masseter muscle. After obtaining the appropriate responses, PRF will be applied at a fixed heat energy of 42 °C for a period of 240 seconds10.

II- Bipolar PRF For bipolar PRF, two RF cannulas will be advanced in the foramen ovale under fluoroscopic guidance. The first (22-gauge, 100 mm, and 10-mm active tip (SMK)) will be placed at the anterior border of the foramen ovale, and then the second (same parameters) will be advanced at the posterior border. The correct position will be confirmed on the lateral position until the correct placement at V2. Sensory and motor testing will be performed as aforementioned in the monopolar PRF to confirm the appropriate capture of the trigeminal nerve. Following obtaining the appropriate responses, PRF will be performed in two cycles, three minutes each, at a temperature of 42ºC and a current of 85 V and a 20-millisecond pulse width13.

02

Conditions studied

  • Trigeminal Neuralgia
  • Refractory Pain

Keywords

  • trigeminal neuralgia
  • Radiofrequency ablation
  • Pulsed radiofrequency
  • Monopolar pulsed radiofrequency
  • Bipolar pulsed radiofrequnency
03

In context

Trigeminal Neuralgia

140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.

This study's planned enrollment of 20 is below the median of 40 across 93 interventional studies indexed under Trigeminal Neuralgia.

Browse Trigeminal Neuralgia studies →

Lead sponsor

Alexandria University is the lead sponsor of 604 studies on the registry; 140 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a definitive diagnosis of classical TN based on the third version of the International Classification of Headache Disorders (ICHD-3).
  2. Either purely paroxysmal classical TN or classical TN with concomitant chronic pain.
  3. Patients with idiopathic TN, with symptomatic clinical topography of V2 and/or V3.
  4. Patients with brain magnetic resonance imaging (MRI) unremarkable for structural etiology for the trigeminal pain.
  5. Patients with medically TN defined as pain persisting beyond three months at a level of ≥5/10 after monotherapy or polytherapy in appropriate medical doses.

Exclusion criteria

Exclusion Criteria:

  1. Painful trigeminal neuropathy based on the third version of the International Classification of Headache Disorders (ICHD-3).
  2. Trigeminal neuralgia with V1 symptomatic clinical topography.
  3. Trigeminal neuralgia comorbid with other atypical facial pain disorders.
  4. Structural TN e.g., due to vascular compression, posterior fossa tumors, central demyelination, ...etc.
  5. Patients exposed to previous radiofrequency procedures, as this may impair the nerve response to current PRF.
  6. Patients who refused to participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Placebo comparator
    Monopolar pulsed radiofrequncy

    Patients with refractory TN undergoing monopolar pulsed radiofrequency

    Procedure: Mopolar pulsed radiofrequency

  • Active comparator
    Bipolar pulsed radiofrequency

    Patients with refractory TN undergoing bipolar pulsed radiofrequency

    Procedure: Bipolar pulsed radiofrequency

Interventions

  • ProcedureBipolar pulsed radiofrequency

    Bipolar pulsed radiofrequency ablation: the active comparator

  • ProcedureMopolar pulsed radiofrequency

    Monopolar pulsed radiofrequency ablation: the placebo

06

What researchers measure

Primary outcomes

  1. Numerical pain scale (NRS)

    50% Pain reduction in the numerical rating scale (NRS)

    Time frame: Two weeks, 1 month, 3 months, and 6 months

Secondary outcomes

  1. Adverse events monitoring (Frequency, severity, seriousness, and causality)

    Frequency, type, and severity of adverse events. Classification of AEs as mild, moderate, or severe. Assessment of causality between the treatment and the AE

    Time frame: 6 months

07

Study locations

2 of 2 sites recruiting
  • Alexandria University Faculty of Medicine
    Alexandria, 21517, Egypt
    Recruiting
    • Eman Hamdy, PhD · Contact
  • Cairo University Kasr Alainy Faculty of Medicine
    Cairo, Egypt
    Recruiting
    • Ahmed Elshal, PhD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06779578
Responsible party
Eman Hamdy (Lecturer in Neurology, Alexandria University) — Principal investigator
First posted
Jan 16, 2025
Start date
Jan 1, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Jan 17, 2025

Study contacts

Eman Hamdy, PhD
Contact
eman.ameen@alexmed.edu.eg
+201061402092
Ahmed Elshal, PhD
Contact
dr.ahmedelshal@gmail.com
+201002998841

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion